Corporate Information And Statement Of Ifrs Compliance [Abstract]
| Concept |
2024-01-01 to 2024-12-31 |
|---|---|
| Corporate information and statement of IFRS compliance [abstract] | |
| Domicile of entity |
Switzerland
|
| Legal form of entity |
AG
|
| Address of entity's registered office |
registered office at Bahnhofstrasse 20, CH-6300, Zug,
|
| Principal place of business |
Switzerland
|
| Description of nature of entity's operations and principal activities |
Oculis is a global late clinical-stage biopharmaceutical company with substantial expertise in therapeutics used to treat ophthalmic and neuro-ophthalmic diseases, engaged in the development of innovative drug candidates which embrace the potential to address significant unmet medical needs for many conditions. The Company’s focus is on advancing therapeutic candidates intended to treat significant and prevalent ophthalmic diseases which result in vision loss, blindness or reduced quality of life. Its mission is to improve patients’ health and quality of life worldwide by developing medicines that save sight and improve eye care for patients, and it intends to become a global leader in the field.
|
| Name of ultimate parent of group |
Oculis Holding
|
| Statement of IFRS compliance [text block] |
(B)
|
| Disclosure of material accounting policy information [text block] |
3
|
| Disclosure of objectives, policies and processes for managing capital [text block] |
Capital management
|